Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 8, 2008, Pages 1350-1355

  Manna, Thais Delia ^a,f   Battistim, Claudilene ^a   Radonsky, Vanessa ^a   Savoldelli, Roberta D ^a   Damiani, Durval ^a   Kok, Fernando ^a   Pearson, Ewan R ^b   Ellard, Sian ^c   Hattersley, Andrew T ^d   Reis, André F ^e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d PENINSULA MEDICAL SCHOOL   (United Kingdom)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f NONE   (Brazil)

Author keywords

C166Y mutation; Glibenclamide; KATP channels; KCNJ11; Neonatal diabetes mellitus; Treatment failure

Indexed keywords

EID: 58849159585     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000800024     Document Type: Article

References (31)

1. von Muhlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med. 1995;333:704-8.
2. Shield JPH, Gardner RJ, Wadsworth EJK, Whiteford ML, James RS, Robinson DO, et al. Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child. 1997;76:F39-F42.
3. Polak M, Cavè H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis. 2007;2:12.
4. Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocrine Rev. 2008;29:265-91.
5. Sperling MA. Neonatal diabetes mellitus: from understudy to center stage. Curr Opin Pediatr. 2005;17:512-8.
6. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838-49.
7. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABBC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355:456-66.
8. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet. 2007;81 (2):375-82.
9. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes. 2008;57(4):1034-42.
10. ATP channels. Physiol Rev. 1998;78:227-45.
11. Reis AF, Velho G. Patologia molecular do receptor de sulfoniluréia (SUR1). Arq Bras Endocrinol Metab. 2000;44:382-9.
12. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467-77.
13. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53:2713-8.
14. Zung A, Glaser B, Nimri R, Zadik Zvi. Glibenclamide treatment in permanent neonatal diabetes activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004;89:5504-7.
15. Klupa T, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki MT. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia. 2005;48: 1029-31.
16. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT. Highdose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care. 2005;28(30):758-9.
17. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good longterm glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalized epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia. 2006;49:2559-63.
18. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54:2503-13.
19. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006;49(6): 1190-7.
20. Masia R, Koster JC, Tumini S, Chiarelli F, Colombo C, Nichols CG, Barbetti F. An ATP-binding mutation (G334D) in KCIMJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes. 2007; 56:328-36.
21. Shimomura K, Horster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, et al. A novel mutation causing DEND syndrome. Neurology. 2007;69:1342-9.
22. Gurgel LC, Crispim F, IMoffs MH, Belzunces E, Rahal MA, Moises RS. Sulfonylurea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function. Diabetes Care. 2007;30:e108.
23. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab. 2008;93:1054-61.
24. Mlynarski W, Tarasov Al, Gach A, Girard CA, Pietrzak I, Zubcevic L, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol. 2007;3:640-5.
25. Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabetic Medicine. 2008;25:277-81.
26. Gloyn AL, Diatloff-Zito C, Edghill EL, Bellanné-Chantelot C, Nivot S, Coutant R, et al. KCNJ11 activating mutations are associated with development delay, epilepsy and neonatal diabetes syndrome and other neurological features. Eur J Hum Gen. 2006;14:824-30.
27. Bahi-Buisson N, Eisermann M, Nivot S, Bellanné-Chantelot C, Dulac O, Bach N, et al. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2. J Child Neurol. 2007;22(9):1147-50.
28. Suzuki S, Makita Y, Mukai T, Matsuo K, ueda O, Fujieda K. Molecular basis of neonatal diabetes in Japanese patients. J Clin Endocrinol Metab. 2007;92(10):3979-85.
29. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Nat Acad Sci USA. 2004;101:17539-44.
30. Shimomura K. The K(ATP) channel and neonatal diabetes. Endocr J. 2008 Jun 20. [Epub ahead of print].
31. Trapp S, Proks P, Tucker SJ, Ashcroft FM. Molecular analysis of ATP-sensitive K channel gating and implications for channel inhibition by ATP. J Gen Physiol. 1998;112:333-49.